UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials

Journal of clinical oncology, 2006-07, Vol.24 (19), p.3128-3135

2006

Volltextzugriff (PDF)

A Prognostic Score for Advanced Hodgkin's Disease

The New England journal of medicine, 1998-11, Vol.339 (21), p.1506-1514

1998

Volltextzugriff (PDF)

The Caregivers Quality of Life Cancer index scale (CQoLC): an exploratory factor analysis for validation in French cancer patients' spouses

Quality of life research, 2013-02, Vol.22 (1), p.119-122

2013

Volltextzugriff (PDF)

Sperm quality before treatment in patients with early stage Hodgkin’s lymphoma enrolled in EORTC-GELA Lymphoma Group trials

Haematologica (Roma), 2009-12, Vol.94 (12), p.1691-1697

2009

Volltextzugriff (PDF)

Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Étude des Lymphomes de l'Adulte

Journal of clinical oncology, 2007-07, Vol.25 (19), p.2825-2832

2007

Volltextzugriff (PDF)

Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2006-04, Vol.24 (10), p.1590-1596

2006

Volltextzugriff (PDF)

Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95

British journal of haematology, 2010-10, Vol.151 (2), p.159-166

2010

Volltextzugriff (PDF)

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

European journal of cancer (1990), 2017-08, Vol.81, p.45-55

2017

Volltextzugriff (PDF)

Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial

International journal of radiation oncology, biology, physics, 2018-04, Vol.100 (5), p.1133-1145

2018

Volltextzugriff (PDF)

Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort

Leukemia & lymphoma, 2016-06, Vol.57 (6), p.1349-1354

2016

Volltextzugriff (PDF)

Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin's lymphoma : Results of a pilot study

International journal of radiation oncology, biology, physics, 1998-01, Vol.40 (2), p.387-390

1998

Volltextzugriff (PDF)

The impact of lymphoma and treatment on male fertility

Expert Review of Hematology, 2010-12, Vol.3 (6), p.775-788

2010

Volltextzugriff (PDF)

Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma

The New England journal of medicine, 2003-06, Vol.348 (24), p.2396-2406

2003

Volltextzugriff (PDF)

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial

The lancet oncology, 2009-12, Vol.10 (12), p.1160-1170

2009

Volltextzugriff (PDF)

ABVD or BEACOPP^sub baseline^ along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

European journal of cancer (1990), 2017-08, Vol.81, p.45

2017

Volltextzugriff (PDF)

Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study

Leukemia & lymphoma, 2014-04, Vol.55 (4), p.848-854

2014

Volltextzugriff (PDF)

ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

European journal of cancer (1990), 2017-08, Vol.81, p.45-55

2017

Volltextzugriff (PDF)

The EORTC strategy in the treatment of Hodgkin's lymphoma

European journal of haematology, 2005-07, Vol.75 (s66), p.135-140

2005

Volltextzugriff (PDF)

CD30-positive cutaneous large cell lymphomas : A comparative study of clinicopathologic and molecular features of 16 cases

American journal of clinical pathology, 1996-04, Vol.105 (4), p.440-450

1996

Volltextzugriff (PDF)

High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series

Journal of clinical oncology, 1998-03, Vol.16 (3), p.864-871

1998

Volltextzugriff (PDF)

Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin’s lymphoma - EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54): Gem-(R)CHOP in untreated aggressive NHL

European journal of haematology, 2011-02, Vol.86 (2), p.111-116

2011

Volltextzugriff (PDF)

Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma - EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54)

European journal of haematology, 2011-02, Vol.86 (2), p.111-116

2011

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(54)
Buchkapitel
(2)

Sprache

Englisch
(53)
Französisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(36)
Life Sciences & Biomedicine
(36)
Science & Technology
(36)
Male
(27)
Female
(24)
Aged
(23)
Middle Aged
(23)
Adult
(19)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Oncology
(18)
Hematologic And Hematopoietic Diseases
(16)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(16)
Hematology
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Neoplasm Staging
(13)
Adolescent
(11)
Antineoplastic Combined Chemotherapy Protocols - Administration & Dosage
(11)
Survival Analysis
(11)
Treatment Outcome
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials

Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC

A Prognostic Score for Advanced Hodgkin's Disease

The Caregivers Quality of Life Cancer index scale (CQoLC): an exploratory factor analysis for validation in French cancer patients' spouses

Sperm quality before treatment in patients with early stage Hodgkin’s lymphoma enrolled in EORTC-GELA Lymphoma Group trials

Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Étude des Lymphomes de l'Adulte

Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma

Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95

Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial

Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort

Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin's lymphoma : Results of a pilot study

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

The impact of lymphoma and treatment on male fertility

Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial

ABVD or BEACOPP^sub baseline^ along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study

ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

The EORTC strategy in the treatment of Hodgkin's lymphoma

CD30-positive cutaneous large cell lymphomas : A comparative study of clinicopathologic and molecular features of 16 cases

High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series

Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin’s lymphoma - EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54): Gem-(R)CHOP in untreated aggressive NHL

Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma - EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54)

Suchergebnisse filtern